Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Free Cash Flow (2018 - 2025)

X4 Pharmaceuticals' Free Cash Flow history spans 8 years, with the latest figure at -$16.0 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 46.29% year-over-year to -$16.0 million; the TTM value through Dec 2025 reached -$86.1 million, up 47.76%, while the annual FY2025 figure was -$86.1 million, 34.37% up from the prior year.
  • Free Cash Flow reached -$16.0 million in Q4 2025 per XFOR's latest filing, up from -$27.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$12.4 million in Q1 2025 to a low of -$68.8 million in Q3 2023.
  • Average Free Cash Flow over 5 years is -$28.5 million, with a median of -$23.4 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: tumbled 256.33% in 2023, then soared 63.16% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$19.1 million in 2021, then decreased by 0.32% to -$19.1 million in 2022, then plummeted by 45.25% to -$27.8 million in 2023, then decreased by 7.34% to -$29.8 million in 2024, then skyrocketed by 46.29% to -$16.0 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Free Cash Flow are -$16.0 million (Q4 2025), -$27.8 million (Q3 2025), and -$29.9 million (Q2 2025).